GRAIL INC

GRALNASDAQ

🏆 #1512 by market capEarnings Nov 11US Equity

$72.60▼ $2.77 (−3.82%)

Live

1h▼ 3.3%

24h▼ 3.8%

7d▼ 2.1%

14d▲ 14.5%

30d▲ 1.1%

1y▲ 115.8%

🏦Market Cap

$3.12B

Small Cap

📈Revenue Growth (YoY)

+17.2%

Healthy

📊Gross Margin

-10.8%

Thin

💵FCF Margin

-178.7%

Thin

⚖️P/S Ratio

18.9x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $71.54 – $72.92
52-Week Range: $29.95 – $118.84
Volume: $4.03B
Avg Volume: $5.12B
Shares Outstanding: 42.9M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $147M
Last Q Revenue: $45M
P/E Ratio: -7.4
P/S Ratio: 18.9x
EPS (TTM): $-9.08
Dividend Yield: 0.00%

Why Investors Own GRAL

✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$147M▲ +17.1% YoY

Gross Margin (TTM)

64.7%▲ +0.0% YoY

Operating Income (TTM)

$45M▲ +17.1% YoY

Free Cash Flow (TTM)

$6M▲ +17.1% YoY

About GRAIL INC

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

🦦